Clinical Trial Update: Efficacy and Safety of Rifaximin-α in Treating MASLD [EARLY_Phase 1]

View source ↗

Summary

This clinical trial update notes an early-phase Phase 1 study evaluating the efficacy and safety of rifaximin-α for metabolic dysfunction-associated steatotic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease | EARLY_Phase 1 | Status: RECRUITING